Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
B-cell depletion with rituximab: a promising treatment for diffuse cutaneous systemic sclerosis van Laar JMArthritis Res Ther 2010[]; 12 (2): 112Recent preclinical and clinical studies lend support to the notion that B-cell depletion is a promising therapeutic target in patients with diffuse cutaneous systemic sclerosis. A recent open-label trial provides further evidence showing marked effects of rituximab treatment on skin thickening, functional ability, and disease activity in conjunction with effects on lesional and circulating B cells and on interleukin-6 and BAFF (B-cell activating factor of tumor necrosis factor family). The excellent safety profile of rituximab in this and other trials warrants further well-designed clinical trials in larger patient groups combined with comprehensive biomarker studies.|Antibodies, Monoclonal, Murine-Derived[MESH]|Antibodies, Monoclonal/*therapeutic use[MESH]|B-Lymphocytes/cytology/*drug effects/immunology[MESH]|Clinical Trials as Topic[MESH]|Humans[MESH]|Immunologic Factors/*therapeutic use[MESH]|Lymphocyte Depletion[MESH]|Recovery of Function[MESH]|Rituximab[MESH]|Scleroderma, Diffuse/*drug therapy/pathology/physiopathology[MESH]|Skin/*drug effects/pathology[MESH]|Treatment Outcome[MESH] |
